Jared Kaltwasser

New research by shows how one of the major scientific breakthroughs of recent years might be used to eliminate HIV infection.

Optometrists say their wide distribution and medical expertise make them ideal candidates to administer the COVID-19 vaccine. As healthcare workers they also want to be prioritized to receive the vaccine.

The idea that social factors affect health outcomes is not new, but new research suggests total number of social determinants of health is a valuable proxy for coronary heart disease risk.

Suppliers of personal protective equipment have come up with innovative ways to meet the demand, but one expert notes the lack of rigorous research into its efficacy.

The Trump administration’s attempts at pulling back the curtain have ended up in court.

A new study finds people who go on to be diagnosed with MS are more likely to have experienced a significant stressful life event, but the author cautions against jumping to cause-and-effect conclusions.

But social distancing and face masks may mean less transmission of flu — and fewer colds.

U.S. healthcare was gearing up for a rebound that includes telehealth. But then the pandemic surged back.

Advocates say a number of regulatory changes could help bring more of these products on to the market.

Patients with major depressive disorder have higher healthcare utilization rates when they experience certain key clinical events, according to a new study.

Are patients with MS taking DMTs at higher risk of infection or case severity during COVID-19? A small study suggests that may not the case with one.

Researchers cost-impact model calculates the cost to be 15 centers PMPY.

Cases of the most common type of liver cancer are expected to be increasingly associated with nonalcoholic steatohepatitits (NASH).

The Institute for Clinical and Economic Review appears to be an important source of information for managed care executives making decisions about treatment and cost.

The Institute for Clinical and Economic Review (ICER) found siponimod has benefits for patients with active secondary progressive multiple sclerosis, but its benefits were in line with other therapies in a crowded marketplace.

Much remains unknown about how precisely multiple sclerosis occurs and advances in patients, but a growing body of research is helping scientists develop new ways to slow, and potentially stop, disease progression.

A new study highlights the role a qualified specialty pharmacist can play in driving down costs across a health plan.

A study of patients with inflammatory conditions who were prescribed biologic disease-modifying anti-rheumatic drugs had lower rates of chronic opioid use if they were adherent to their biologic therapy, according to new research.